TREACE MEDICAL CONCEPTS, INC. Cash Flow Statement
TMCI|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
TREACE MEDICAL CONCEPTS, INC. used $35M in operating cash flow and negative free cash flow of $46M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$49.5M | -$42.8M | -$20.6M | -$3.7M | -$4.3M |
| Depreciation & Amortization | $5.4M | $2.1M | $685.0K | $1.2M | $793.0K |
| Operating Cash Flow | -$34.6M | -$30.6M | -$17.2M | -$4.5M | -$7.7M |
| Capital Expenditures | $11.5M | $14.8M | $2.7M | $1.1M | $1.2M |
| Free Cash Flow | -$46.0M | -$45.5M | -$19.9M | -$5.6M | -$8.9M |
| FCF Margin | -24.6% | -32.1% | -21.1% | -9.7% | -22.5% |